NASDAQ$MAZE
Maze Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Maze Therapeutics Inc Q1 fiscal 2026: $20.0M revenue, $24.2M net loss
for the year ended December 31, 2025, as filed with the SEC on March 25, 2026, or the 2025 10-K. (SEC accession 0001193125-26-219430)
- Revenue: $20.0M
- Net loss: $24.2M
- Diluted EPS: $-0.45
- Operating income: $-26.6M
Headline financials
Revenue & EPS history
Maze Therapeutics Inc · Revenue · Quarterly
$20M
Q1 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 2 quarterly earnings reports · overlaid with Q1 2026
+0.3%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+61.0%
Avg return
30 days after
67%
2 / 3 earnings
Positive
+2.0%
Q2 2025
Best reaction
-2.1%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | +0.4% | — | |
| Q3 2025 | -2.1% | +6.6% | +37.8% | |
| Q2 2025 | +2.0% | +0.2% | +84.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro